Silence Therapeutics plc (NASDAQ:SLN) Receives $54.75 Average Price Target from Brokerages

Silence Therapeutics plc (NASDAQ:SLN) has been assigned an average rating of “Buy” from the six research firms that are currently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $54.75.

SLN has been the topic of several research reports. BMO Capital Markets reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research report on Monday, December 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research note on Wednesday, January 29th. Chardan Capital reissued a “buy” rating and set a $55.00 target price on shares of Silence Therapeutics in a research report on Tuesday, December 10th. William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research report on Tuesday, November 19th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $49.00 price objective on shares of Silence Therapeutics in a research report on Tuesday, October 8th.

Silence Therapeutics Stock Performance

Shares of SLN stock opened at $5.61 on Friday. The firm has a market capitalization of $167.90 million, a price-to-earnings ratio of -3.57 and a beta of 1.08. Silence Therapeutics has a one year low of $4.82 and a one year high of $27.72. The company has a 50 day moving average price of $6.52 and a 200 day moving average price of $13.52.

Institutional Investors Weigh In On Silence Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. purchased a new stake in Silence Therapeutics during the 4th quarter worth approximately $69,000. FNY Investment Advisers LLC bought a new stake in shares of Silence Therapeutics in the fourth quarter worth $120,000. GAMMA Investing LLC raised its holdings in Silence Therapeutics by 609.2% in the fourth quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock valued at $42,000 after acquiring an additional 5,233 shares in the last quarter. Y Intercept Hong Kong Ltd boosted its stake in Silence Therapeutics by 22.9% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 21,078 shares of the company’s stock valued at $383,000 after acquiring an additional 3,923 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in Silence Therapeutics by 219.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company’s stock worth $8,505,000 after acquiring an additional 321,300 shares in the last quarter. 98.73% of the stock is owned by institutional investors and hedge funds.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.